

## **Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update**

TEL AVIV, Israel, Feb. 14, 2024 /PRNewswire/ -- [Chemomab Therapeutics Ltd.](#) (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its fourth quarter and full year 2023 financial results and providing a business update on March 7, 2024, at 7:00 am Eastern Time.

Investors who would like to discuss the financial results or business update after the press release is issued are invited to contact the company at [IR@chemomab.com](mailto:IR@chemomab.com).

### **About Chemomab Therapeutics Ltd.**

Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from three clinical trials of CM-101 in patients, including a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with topline data expected midyear 2024. Chemomab's CM-101 program for the treatment of systemic sclerosis is Phase 2-ready. For more information about Chemomab, visit [chemomab.com](https://chemomab.com).

### **Contacts:**

#### **Media and Investors:**

Barbara Lindheim  
Consulting Vice President, Investor & Public Relations,  
Strategic Communications  
Phone: +1 917-355-9234  
[barbara.lindheim@chemomab.com](mailto:barbara.lindheim@chemomab.com)  
[IR@chemomab.com](mailto:IR@chemomab.com)

SOURCE Chemomab Therapeutics Ltd

---